CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
Dexamethasone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00966693
NCT00966693Phase 2Completed
CompareCT.gov

Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

M.D. Anderson Cancer Center·interventional·Posted Aug 27, 2009·Updated Nov 4, 2020

In Brief

A Phase 2 clinical trial evaluating Dexamethasone, Lenalidomide, and 1 other intervention for Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma. Completed, enrolled 77 participants across 1 site.

Detailed Summary

This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide, and how well they work with dexamethasone in treating participants with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, thalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 27, 2009
Enrollment StartAug 25, 2009
Primary CompletionJul 20, 2018
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 16.8 years ago

Interventions

Dexamethasonedrug

Given PO

Lenalidomidedrug

Given PO

Thalidomidedrug

Given PO